T-cell acute lymphoblastic leukemia (T-ALL) is a clonal malignant disease. Isocitrate Dehydrogenase 1-R123 (IDH1-R132 H) is related to T-ALL progression. This study explored the role of IDH1-R132H in T-ALL. Molt-4 cells with IDH1-R132H mutation were constructed by retroviral transfection of IDH1-R132H and T-ALL xenotransplantation mouse model was established by injection of Molt-4 cells through the tail vein. Infiltration of the liver, spleen, and bone marrow and the percentage of CD45-positive T-ALL cells in them were detected. Cell proliferation, apoptosis, and invasion were evaluated after the intervention of Notch1, PTEN, or PI3K expression. The leukocyte number was increased, the spleen was enlarged, infiltration in bone marrow, spleen, and liver tissue was worsened and the percentage of hCD45-positive T-ALL cells was increased by IDH1-R132H mutation, which promoted T-ALL deterioration. IDH1-R132H mutation promoted proliferation, invasion, and inhibited apoptosis of T-ALL cells, which were reversed by inhibition of Notch1. IDH1-R132H mutation upregulated HES1 expression and downregulated PTEN expression by activating the Notch1 pathway, while inhibition of Notch1 reversed these changes. PTEN inhibited the PI3K/AKT pathway activation. PTEN overexpression reversed IDH1-R132H mutation effect on promoting malignant behaviors of T-ALL cells. IDH1-R132H mutation inhibited PTEN expression by activating the Notch1/HES1 pathway, activated the PI3K/AKT pathway, thus promoting malignant behaviors of T-ALL cells.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.tice.2021.101674 | DOI Listing |
J Neurooncol
January 2025
Department of Neurosurgery, NYU Langone Health and NYU Grossman School of Medicine, 530 1st Avenue, Skirball Suite 8R, New York, NY, 10016, USA.
Unlabelled: QUESTIONS AND RECOMMENDATIONS FROM THE PRIOR VERSION OF THESE GUIDELINES WITHOUT CHANGE: TARGET POPULATION: Adult patients (age ≥ 18 years) who have suspected low-grade diffuse glioma.
Question: What are the optimal neuropathological techniques to diagnose low-grade diffuse glioma in the adult?
Recommendation: Level I Histopathological analysis of a representative surgical sample of the lesion should be used to provide the diagnosis of low-grade diffuse glioma. Level III Both frozen section and cytopathologic/smear evaluation should be used to aid the intra-operative assessment of low-grade diffuse glioma diagnosis.
Neurooncol Adv
November 2024
Laboratory of Molecular Neuro-Oncology, Department of Neurology, Clinical Neuroscience Centre, University Hospital and University of Zurich, Zurich, Switzerland.
Background: Gliomas, the most frequent malignant primary brain tumors, lack curative treatments. Understanding glioma-specific molecular alterations is crucial to develop novel therapies. Among them, the biological consequences of the isocitrate dehydrogenase 1 gene mutation ( ) remain inconclusive despite its early occurrence and widespread expression.
View Article and Find Full Text PDFInt J Mol Sci
November 2024
School of Medicine and Life Sciences, Far Eastern Federal University, Vladivostok 690922, Russia.
Mutations in IDH1 and TP53 have a significant impact on glioma prognosis and progression; however, their roles in tumor cell invasion in terms of interactions with particular components of the extracellular matrix (ECM) are still unclear. Using gene editing protocol based on CRISPR-Cas 9 with cytidine deaminase, we introduced point mutations into U87MG glioblastoma cells to establish modified cell lines with heterozygous IDH1 R132H, homozygous TP53 R248Q and heterozygous IDH1 R132H, homozygous TP53 R248Q genotypes. A comparative study of cell migration on major ECM components was carried out by high-content microscopy.
View Article and Find Full Text PDFNeurooncol Pract
December 2024
Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MinnesotaUSA.
Cancers (Basel)
September 2024
Department of Neurosciences, Division of Neurosurgery, Policlinico "G. Rodolico-S. Marco", University Hospital, 95123 Catania, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!